150 related articles for article (PubMed ID: 23433742)
41. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
[TBL] [Abstract][Full Text] [Related]
42. Management of advanced-stage and recurrent endometrial cancer.
Ray M; Fleming G
Semin Oncol; 2009 Apr; 36(2):145-54. PubMed ID: 19332249
[TBL] [Abstract][Full Text] [Related]
43. The benefits of a gynecologic oncologist: a pattern of care study for endometrial cancer treatment.
Roland PY; Kelly FJ; Kulwicki CY; Blitzer P; Curcio M; Orr JW
Gynecol Oncol; 2004 Apr; 93(1):125-30. PubMed ID: 15047225
[TBL] [Abstract][Full Text] [Related]
44. Adjuvant treatment for early-stage endometrial cancer.
Zighelboim I; Powell MA
Clin Obstet Gynecol; 2011 Jun; 54(2):245-55. PubMed ID: 21508694
[TBL] [Abstract][Full Text] [Related]
45. Novel molecular profiles of endometrial cancer-new light through old windows.
Doll A; Abal M; Rigau M; Monge M; Gonzalez M; Demajo S; Colás E; Llauradó M; Alazzouzi H; Planagumá J; Lohmann MA; Garcia J; Castellvi S; Ramon y Cajal J; Gil-Moreno A; Xercavins J; Alameda F; Reventós J
J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):221-9. PubMed ID: 18061438
[TBL] [Abstract][Full Text] [Related]
46. Molecular characteristics and risk factors in endometrial cancer: what are the treatment and preventative strategies?
Ellis PE; Ghaem-Maghami S
Int J Gynecol Cancer; 2010 Oct; 20(7):1207-16. PubMed ID: 21495229
[TBL] [Abstract][Full Text] [Related]
47. An update on the pharmacotherapy for endometrial cancer.
Amadio G; Masciullo V; Stefano L; Scambia G
Expert Opin Pharmacother; 2013 Dec; 14(18):2501-9. PubMed ID: 24138224
[TBL] [Abstract][Full Text] [Related]
48. Recurrent endometrial cancer.
Del Carmen MG; Boruta DM; Schorge JO
Clin Obstet Gynecol; 2011 Jun; 54(2):266-77. PubMed ID: 21508696
[TBL] [Abstract][Full Text] [Related]
49. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
Slomovitz BM; Coleman RL
Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
[TBL] [Abstract][Full Text] [Related]
50. SEOM clinical guidelines for endometrial cancer (2017).
Santaballa A; Matías-Guiu X; Redondo A; Carballo N; Gil M; Gómez C; Gorostidi M; Gutierrez M; Gónzalez-Martín A
Clin Transl Oncol; 2018 Jan; 20(1):29-37. PubMed ID: 29238915
[TBL] [Abstract][Full Text] [Related]
51. Oncogene alterations in endometrial carcinosarcomas.
Biscuola M; Van de Vijver K; Castilla MÁ; Romero-Pérez L; López-García MÁ; Díaz-Martín J; Matias-Guiu X; Oliva E; Palacios Calvo J
Hum Pathol; 2013 May; 44(5):852-9. PubMed ID: 23199529
[TBL] [Abstract][Full Text] [Related]
52. An update on the current pharmacotherapy for endometrial cancer.
de Haydu C; Black JD; Schwab CL; English DP; Santin AD
Expert Opin Pharmacother; 2016; 17(4):489-99. PubMed ID: 26629895
[TBL] [Abstract][Full Text] [Related]
53. Recent progress in the use of pharmacotherapy for endometrial cancer.
Giudice E; Salutari V; Ricci C; Nero C; Carbone MV; Musacchio L; Ghizzoni V; Perri MT; Camarda F; Tronconi F; Lorusso D; Scambia G
Expert Opin Pharmacother; 2023 Jan; 24(1):83-94. PubMed ID: 35912837
[TBL] [Abstract][Full Text] [Related]
54. Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification.
Jamieson A; Huvila J; Thompson EF; Leung S; Chiu D; Lum A; McConechy M; Grondin K; Aguirre-Hernandez R; Salvador S; Kean S; Samouelian V; Gougeon F; Azordegan N; Lytwyn A; Parra-Herran C; Offman S; Gotlieb W; Irving J; Kinloch M; Helpman L; Scott SA; Vicus D; Plante M; Huntsman DG; Gilks CB; Talhouk A; McAlpine JN
Gynecol Oncol; 2022 May; 165(2):201-214. PubMed ID: 35246332
[TBL] [Abstract][Full Text] [Related]
55. Adjuvant Treatment and Clinical Trials in Elderly Patients With Endometrial Cancer: A Time for Change?
Clark LH; Jackson AL; Gehrig PA; Bae-Jump V; Van Le L; Ko EM
Int J Gynecol Cancer; 2016 Feb; 26(2):282-9. PubMed ID: 26745698
[TBL] [Abstract][Full Text] [Related]
56. Molecular Profiling of Endometrial Cancer From TCGA to Clinical Practice.
Jamieson A; McAlpine JN
J Natl Compr Canc Netw; 2023 Feb; 21(2):210-216. PubMed ID: 36791751
[TBL] [Abstract][Full Text] [Related]
57. Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer.
Gordhandas S; Zammarrelli WA; Rios-Doria EV; Green AK; Makker V
J Natl Compr Canc Netw; 2023 Feb; 21(2):217-226. PubMed ID: 36791759
[TBL] [Abstract][Full Text] [Related]
58. Role of circulating free alu DNA in endometrial cancer.
Tanaka H; Tsuda H; Nishimura S; Nomura H; Kataoka F; Chiyoda T; Tanaka K; Iguchi Y; Susumu N; Aoki D
Int J Gynecol Cancer; 2012 Jan; 22(1):82-6. PubMed ID: 22146763
[TBL] [Abstract][Full Text] [Related]
59. Fertility-Sparing Strategies for Early-Stage Endometrial Cancer: Stepping towards Precision Medicine Based on the Molecular Fingerprint.
Gullo G; Cucinella G; Chiantera V; Dellino M; Cascardi E; Török P; Herman T; Garzon S; Uccella S; Laganà AS
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614253
[TBL] [Abstract][Full Text] [Related]
60. Therapeutic Targets and Opportunities in Endometrial Cancer: Update on Endocrine Therapy and Nonimmunotherapy Targeted Options.
MacKay HJ; Freixinos VR; Fleming GF
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-11. PubMed ID: 32239967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
